EMEA deltog i en række møder om risikovurdering i tilknytning til nye former for syntetisk narkotika og misbrug af lægemidler.
The EMEA participated in a number of meetings in 2000 relating to evaluation of risks associated with new synthetic drugs and the abuse of medicinal products.